In agreement, co-therapy with recombinant TRAIL and IL-12 proteins has been found to significantly sensitize HCC cells to TRAIL’s apoptotic effect [27]; and treatment with IL-12 has shown to upregulate TRAIL expression on NK cells and contributes to IFN-γ-dependent NK cell protection from tumor metastasis [28]. This evidence concerns the gene IFNG and hepatocellular carcinoma.